Indaptus Therapeutics
INDP
25 hedge funds and large institutions have $72.2M invested in Indaptus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
10% more capital invested
Capital invested by funds: $65.6M → $72.2M (+$6.63M)
4% less funds holding
Funds holding: 26 → 25 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
87% less call options, than puts
Call options by funds: $11K | Put options by funds: $87K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$2.67M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$1.77M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.22M |
| 4 |
DMK
David M. Knott
|
+$1.21M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$903K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$13M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.4M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$200K |
| 4 |
Renaissance Technologies
New York
|
-$200K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$133K |
INDP Hedge Fund Activity: Q3 2018 in Review
25 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2018, worth a combined $72.2M — up 10% from $65.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of INDP and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 10 added.
The largest buyer was Harel Insurance Investments & Financial Services, adding an estimated $2.67M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $13M sold.
- 25 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2018, down from 26 in Q2 2018.
- Funds reported $72.2M of Indaptus Therapeutics stock for Q3 2018, up 10% quarter-over-quarter.
- 5 funds opened new Indaptus Therapeutics positions in Q3 2018 and 6 closed out, a net change of -1 holder.
- The largest Indaptus Therapeutics buyer in Q3 2018 was Harel Insurance Investments & Financial Services, an estimated $2.67M added.
- The largest Indaptus Therapeutics seller in Q3 2018 was Acuta Capital Partners, an estimated $13M sold.
Based on aggregated 13F filings for Q3 2018.